Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPAJ41)

Drug Name
BIIB-021 Drug Info
Synonyms
CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Cross-matching ID
PubChem CID
16736529
ChEBI ID
CHEBI:90687
CAS Number
CAS 848695-25-0
TTD Drug ID
DMPAJ41

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Heat shock protein 90 alpha (HSP90A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cromoglicate DM74LZK Asthma CA23 Approved [3]
Amlexanox DM0DQM5 Respiratory tract inflammation CA07 Approved [3]
NVP-AUY922 DMTYXQF Multiple myeloma 2A83 Phase 2 [4]
KW-2478 DMJGL72 Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
VER 50589 DMFLZPC Breast cancer 2C60-2C65 Phase 2 [4]
Tanespimycin DMNLQHK Breast cancer 2C60-2C65 Phase 2 [6]
Efungumab DMBHP56 Breast cancer 2C60-2C65 Phase 2 [7]
SNX-5422 DMIU0VP Haematological malignancy 2B33.Y Phase 1/2 [8]
PU3 DMJO0BP Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Debio 0932 DMWP3G1 Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT00618319) An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST). U.S. National Institutes of Health.
2 BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
3 Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
4 Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
5 Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
6 Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
7 Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
8 SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
9 Clinical pipeline report, company report or official report of Debiopharm (2011).